Chargement en cours...
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
A benefit of temozolomide (TMZ) is that myelotoxicity is uncommon. Recently, several small series have reported significant myelotoxicity resulting in treatment delays or death. The ability to predict risk of myelotoxicity may influence patient care. We retrospectively reviewed 680 malignant glioma...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Duke University Press
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2802402/ https://ncbi.nlm.nih.gov/pubmed/19179423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-120 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|